ResMed, Inc.

Stocks

RMD

US7611521078

Market Closed - NYSE Other stock markets 04:00:02 2026-07-22 pm EDT			5-day change	1st Jan Change
192.91 ^USD	-1.48%		-0.05%	-19.91%

Jul. 21	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
Jul. 17	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT

Transcript : ResMed Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 04

Published on 06/02/2026 at 07:35 pm EDT - Modified on 06/03/2026 at 03:50 am EDT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Brandon Vazquez (Analysts)

Hello, everybody. My name is Brandon Vazquez. For those of you who I haven't met before, I'm 1 of William Blair's medical device analyst, also cover animal

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about ResMed, Inc.

Jul. 21	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
Jul. 17	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT
Jul. 15	Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating	MT
Jul. 14	Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating	MT
Jul. 13	Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270	MT
Jul. 13	Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34	MT
Jul. 10	Jefferies Adjusts Price Target on ResMed to $225 From $240	MT
Jul. 09	Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing	MT
Jul. 09	Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight	MT
Jul. 08	ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says	MT
Jul. 08	ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says	MT
Jul. 08	Wells Fargo Adjusts Price Target on ResMed to $225 From $227	MT
Jul. 08	RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating	MT
Jul. 08	Deals of the day-Mergers and acquisitions	RE
Jul. 08	Australian Shares Fall; ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $490 Million	MT